Cargando…
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184836/ https://www.ncbi.nlm.nih.gov/pubmed/37197732 http://dx.doi.org/10.6004/jadpro.2023.14.3.12 |